Swiss-founded, Nasdaq-listed SOPHiA Genetics, an Ai-driven precision medicine company, has closed a public offering with total gross proceeds of US$57.5m.
The company sold 12,104,900 ordinary shares at US$4.75 per share, which included the 1,578,900 ordinary shares issued upon exercise in full by the underwriters of their option to purchase additional shares. All of the ordinary shares were sold by the company.
Proceeds are earmarked for platform expansion, new applications, new geographies and new partnerships.
TD Cowen was lead bookrunner. Guggenheim Securities was bookrunner, and BTIG and Craig-Hallum were lead managers.
In July 2021, SOPHiA IPO’d raising US$234m. The company, founded in 2011 as a startup at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine.
In October 2020, the company raised US$110m in a Series F round of funding led by aMoon and Hitachi Ventures.
